Cyclacel Pharmaceuticals (NASDAQ:CYCC) Shares Down 7.8% – Time to Sell?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) was down 7.8% during mid-day trading on Monday . The stock traded as low as $3.62 and last traded at $3.74. Approximately 130,935 shares were traded during trading, an increase of 30% from the average daily volume of 100,957 shares. The stock had previously closed at $4.05.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Cyclacel Pharmaceuticals in a report on Saturday. They issued a “sell” rating on the stock.

Cyclacel Pharmaceuticals Stock Down 11.5%

The stock has a fifty day moving average of $4.32 and a two-hundred day moving average of $5.57. The stock has a market cap of $744.34 million, a price-to-earnings ratio of -0.38 and a beta of 0.52.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its earnings results on Wednesday, April 2nd. The biotechnology company reported ($5.28) earnings per share for the quarter, missing the consensus estimate of ($4.64) by ($0.64). Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million.

Cyclacel Pharmaceuticals Dividend Announcement

The firm also recently announced a dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 29th were issued a dividend of $2.40 per share. The ex-dividend date of this dividend was Tuesday, April 29th. Cyclacel Pharmaceuticals’s dividend payout ratio (DPR) is currently -4.29%.

Insider Buying and Selling

In related news, CEO David E. Lazar sold 12,164,301 shares of the stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $0.48, for a total transaction of $5,838,864.48. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 68.00% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.